Spongionella secondary metabolites protect mitochondrial function in cortical neurons against oxidative stress

Marine Drugs

Volumn 12, Issue 2, 2014, Pages 700-718

  Leirós, Marta ^a   Sánchez, Jon A ^a   Alonso, Eva ^a   Rateb, Mostafa E ^b,c   Houssen, Wael E ^b,d   Ebel, Rainer ^b   Jaspars, Marcel ^b   Alfonso, Amparo ^a   Botana, Luis M ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c Beni Suef University   (Egypt)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Diterpenes; Mitochondrial function; Neurodegenerative disorders; Oxidative stress; Porifera

Indexed keywords

CALCIUM ION; CASPASE 3; DITERPENE; GLUTATHIONE; GRACILIN A; GRACILIN H; GRACILIN J; GRACILIN K; GRACILIN L; HYDROGEN PEROXIDE; REACTIVE OXYGEN METABOLITE; TETRAHYDROAPLYSULPHURIN 1; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN CELL; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ISOLATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; FETUS; IN VITRO STUDY; MITOCHONDRION; MOUSE; NEUROBLASTOMA CELL; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SPONGE (PORIFERA); SPONGIONELLA; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CEREBRAL CORTEX; DITERPENES; HYDROGEN PEROXIDE; MICE; MITOCHONDRIA; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PORIFERA;

EID: 84896709338     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md12020700     Document Type: Article

References (41)

1. Thomas, T.R.; Kavlekar, D.P.; LokaBharathi, P.A. Marine drugs from sponge-microbe association - A review. Mar. Drugs 2010, 8, 1417-1468.
2. Van Soest, R.W.; Boury-Esnault, N.; Vacelet, J.; Dohrmann, M.; Erpenbeck, D.; de Voogd, N.J.; Santodomingo, N.; Vanhoorne, B.; Kelly, M.; Hooper, J.N. Global diversity of sponges (Porifera). PLoS One 2012, 7, e35105.
3. Abbas, S.; Kelly, M.; Bowling, J.; Sims, J.; Waters, A.; Hamann, M. Advancement into the Arctic region for bioactive sponge secondary metabolites. Mar. Drugs 2011, 9, 2423-2437.
4. Sagar, S.; Kaur, M.; Minneman, K.P. Antiviral lead compounds from marine sponges. Mar. Drugs 2010, 8, 2619-2638.
5. Mollica, A.; Locatelli, M.; Stefanucci, A.; Pinnen, F. Synthesis and bioactivity of secondary metabolites from marine sponges containing dibrominated indolic systems. Molecules 2012, 17, 6083-6099.
6. Hong, S.; Kim, S.H.; Rhee, M.H.; Kim, A.R.; Jung, J.H.; Chun, T.; Yoo, E.S.; Cho, J.Y. In vitro anti-inflammatory and pro-aggregative effects of a lipid compound, petrocortyne A, from marine sponges. Naunyn Schmiedebergs Arch. Pharmacol. 2003, 368, 448-456.
7. Lysek, N.; Kinscherf, R.; Claus, R.; Lindel, T. L-5-Hydroxytryptophan: Antioxidant and anti-apoptotic principle of the intertidal sponge Hymeniacidon heliophila. Z. Naturforsch. C 2003, 58, 568-572.
8. Petri, S.; Korner, S.; Kiaei, M. Nrf2/ARE Signaling pathway: Key mediator in oxidative stress and potential therapeutic target in ALS. Neurol. Res. Int. 2012, 2012, 878030.
9. Sasaki, S.; Tozawa, T.; van Wagoner, R.M.; Ireland, C.M.; Harper, M.K.; Satoh, T. Strongylophorine-8, a pro-electrophilic compound from the marine sponge Petrosia (Strongylophora) corticata, provides neuroprotection through Nrf2/ARE pathway. Biochem. Biophys. Res. Commun. 2011, 415, 6-10.
10. Tahtouh, T.; Elkins, J.M.; Filippakopoulos, P.; Soundararajan, M.; Burgy, G.; Durieu, E.; Cochet, C.; Schmid, R.S.; Lo, D.C.; Delhommel, F.; et al. Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B. J. Med. Chem. 2012, 55, 9312-9330.
11. Rateb, M.E.; Houssen, W.E.; Schumacher, M.; Harrison, W.T.; Diederich, M.; Ebel, R.; Jaspars, M. Bioactive diterpene derivatives from the marine sponge Spongionella sp. J. Nat. Prod. 2009, 72, 1471-1476.
12. Gandhi, S.; Abramov, A.Y. Mechanism of oxidative stress in neurodegeneration. Oxid. Med. Cell. Longev. 2012, 2012, 428010.
13. Wang, X.; Michaelis, E.K. Selective neuronal vulnerability to oxidative stress in the brain. Front. Aging Neurosci. 2010, 2, 12.
14. Melo, A.; Monteiro, L.; Lima, R.M.; Oliveira, D.M.; Cerqueira, M.D.; El-Bacha, R.S. Oxidative stress in neurodegenerative diseases: Mechanisms and therapeutic perspectives. Oxid. Med. Cell. Longev. 2011, 2011, 467180.
15. Zampagni, M.; Wright, D.; Cascella, R.; D'Adamio, G.; Casamenti, F.; Evangelisti, E.; Cardona, F.; Goti, A.; Nacmias, B.; Sorbi, S.; et al. Novel S-acyl glutathione derivatives prevent amyloid oxidative stress and cholinergic dysfunction in Alzheimer disease models. Free Radic. Biol. Med. 2012, 52, 1362-1371.
16. Miriyala, S.; Spasojevic, I.; Tovmasyan, A.; Salvemini, D.; Vujaskovic, Z.; St Clair, D.; Batinic-Haberle, I. Manganese superoxide dismutase, MnSOD and its mimics. Biochim. Biophys. Acta 2012, 1822, 794-814.
17. Paupe, V.; Dassa, E.P.; Goncalves, S.; Auchere, F.; Lonn, M.; Holmgren, A.; Rustin, P. Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia. PLoS One 2009, 4, e4253.
18. Jones, Q.R.; Warford, J.; Rupasinghe, H.P.; Robertson, G.S. Target-based selection of flavonoids for neurodegenerative disorders. Trends Pharmacol. Sci. 2012, 33, 602-610.
19. Ola, M.S.; Nawaz, M.; Ahsan, H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol. Cell. Biochem. 2011, 351, 41-58.
20. Circu, M.L.; Aw, T.Y. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic. Biol. Med. 2010, 48, 749-762.
21. Varming, T.; Drejer, J.; Frandsen, A.; Schousboe, A. Characterization of a chemical anoxia model in cerebellar granule neurons using sodium azide: Protection by nifedipine and MK-801. J. Neurosci. Res. 1996, 44, 40-46.
22. Triana-Vidal, L.E.; Carvajal-Varona, S.M. Protective effect of galantamine against oxidative damage using human lymphocytes: A novel in vitro model. Arch. Med. Res. 2013, 44, 85-92.
23. Facecchia, K.; Fochesato, L.A.; Ray, S.D.; Stohs, S.J.; Pandey, S. Oxidative toxicity in neurodegenerative diseases: Role of mitochondrial dysfunction and therapeutic strategies. J. Toxicol. 2011, 2011, 683728.
24. Crouzin, N.; Ferreira, M.C.; Cohen-Solal, C.; Barbanel, G.; Guiramand, J.; Vignes, M. Neuroprotection induced by vitamin E against oxidative stress in hippocampal neurons: Involvement of TRPV1 channels. Mol. Nutr. Food Res. 2010, 54, 496-505.
25. Giordano, G.; Hong, S.; Faustman, E.; Costa, L. Measurements of Cell Death in Neuronal and Glial Cells. In In Vitro Neurotoxicology. Methods and Protocols, Methods in Molecular Biology; Humana Press: Totowa, NJ, USA, 2011; Volume 758, pp. 171-178.
26. Parekh, A.B.; Penner, R. Store depletion and calcium influx. Physiol. Rev. 1997, 77, 901-930.
27. Putney, J.W., Jr. A model for receptor-regulated calcium entry. Cell Calcium 1986, 7, 1-12.
28. Dispersyn, G.; Nuydens, R.; Connors, R.; Borgers, M.; Geerts, H. Bcl-2 protects against FCCP-induced apoptosis and mitochondrial membrane potential depolarization in PC12 cells. Biochim. Biophys. Acta 1999, 1428, 357-371.
29. Karami-Mohajeri, S.; Abdollahi, M. Mitochondrial dysfunction and organophosphorus compounds. Toxicol. Appl. Pharmacol. 2013, 270, 39-44.
30. Kajta, M.; Trotter, A.; Lason, W.; Beyer, C. Impact of 17beta-estradiol on cytokine-mediated apoptotic effects in primary hippocampal and neocortical cell cultures. Brain Res. 2006, 1116, 64-74.
31. Calkins, M.J.; Johnson, D.A.; Townsend, J.A.; Vargas, M.R.; Dowell, J.A.; Williamson, T.P.; Kraft, A.D.; Lee, J.M.; Li, J.; Johnson, J.A. The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid. Redox Signal. 2009, 11, 497-508.
32. Joshi, G.; Johnson, J.A. The Nrf2-ARE pathway: A valuable therapeutic target for the treatment of neurodegenerative diseases. Recent Pat. CNS Drug Discov. 2012, 7, 218-229.
33. Cagle, P.T.; Allen, T.C. Lung cancer genotype-based therapy and predictive biomarkers: Present and future. Arch. Pathol. Lab. Med. 2012, 136, 1482-1491.
34. Nirmal, N.; Praba, G.O.; Velmurugan, D. Modeling studies on phospholipase A2-inhibitor complexes. Indian J. Biochem. Biophys. 2008, 45, 256-262.
35. Sun, G.Y.; Xu, J.; Jensen, M.D.; Simonyi, A. Phospholipase A2 in the central nervous system: Implications for neurodegenerative diseases. J. Lipid Res. 2004, 45, 205-213.
36. Rueda, A.; Losada, A.; Fernandez, R.; Cabanas, C.; Garcia-Fernandez, L.F.; Reyes, F.; Cuevas, C. Gracilins G-I, Cytotoxic Bisnorditerpenes from Spongionella pulchella, and the Anti-Adhesive Properties of Gracilin B. Lett. Drug Des. Discov. 2006, 3, 753-760.
37. Vale, C.; Alonso, E.; Rubiolo, J.A.; Vieytes, M.R.; LaFerla, F.M.; Gimenez-Llort, L.; Botana, L.M. Profile for amyloid-beta and tau expression in primary cortical cultures from 3xTg-AD mice. Cell. Mol. Neurobiol. 2010, 30, 577-590.
38. Alonso, E.; Vale, C.; Vieytes, M.R.; Laferla, F.M.; Gimenez-Llort, L.; Botana, L.M. 13-Desmethyl spirolide-C is neuroprotective and reduces intracellular Abeta and hyperphosphorylated tau in vitro. Neurochem. Int. 2011, 59, 1056-1065.
39. Alonso, E.; Vale, C.; Vieytes, M.R.; Laferla, F.M.; Gimenez-Llort, L.; Botana, L.M. The cholinergic antagonist gymnodimine improves Abeta and tau neuropathology in an in vitro model of Alzheimer disease. Cell. Physiol. Biochem. 2011, 27, 783-794.
40. White, M.G.; Wang, Y.; Akay, C.; Lindl, K.A.; Kolson, D.L.; Jordan-Sciutto, K.L. Parallel high throughput neuronal toxicity assays demonstrate uncoupling between loss of mitochondrial membrane potential and neuronal damage in a model of HIV-induced neurodegeneration. Neurosci. Res. 2011, 70, 220-229.
41. Kim, E.J.; Kwon, K.J.; Park, J.Y.; Lee, S.H.; Moon, C.H.; Baik, E.J. Neuroprotective effects of prostaglandin E2 or cAMP against microglial and neuronal free radical mediated toxicity associated with inflammation. J. Neurosci. Res. 2002, 70, 97-107.